STOCK TITAN

InVitro Intl (IVRO) Stock Price, News & Analysis

IVRO OTC
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
49 90 sessions, October 28, 2025 to November 9, 2026
Largest daily move
+55.3% close of August 17, 2026
1-year change
-17.2% closing prices, October 28, 2025 to November 9, 2026
1-month change
+16.7% closing prices, October 2, 2026 to November 9, 2026

Company Description

InVitro International (OTCQB: IVRO) is described in its public communications as a pioneer developer and marketer of globally approved NON-Animal test technologies. The company is associated with the pharmaceutical preparation manufacturing industry and focuses on in vitro safety testing methods that do not rely on animal testing. According to its press releases, InVitro International has been active for decades and emphasizes a long-term vision of helping industry move from animal-based safety testing to in vitro testing.

InVitro International highlights that its NON-Animal test technologies are used for safety testing and that its methods have received global approvals. The company states that it serves large industries, mentioning cosmetics, chemical companies, and manufacturers of various adhesives as examples of markets where its in vitro test methods are applied. These customers are described as being located globally, reflecting the company’s focus on international adoption of non-animal testing approaches.

In its public statements, the company links its business to a broader global movement toward animal welfare and regulatory acceptance of non-animal testing. InVitro International notes that regulatory agencies in multiple regions have announced plans to cease funding for animal testing and that some agencies indicate they will accept OECD-validated non-animal test results. The company positions its test methods as aligned with these regulatory directions, stating that it offers such validated non-animal test methods.

InVitro International also comments on its financial and strategic direction. The company reports a long multi-year record of profitability in its fiscal updates and describes a strategy that includes both organic growth and growth through mergers and acquisitions. Public releases mention efforts to pursue mergers with privately owned testing laboratories, including a Memorandum of Understanding (MOU) to merge with a European-based organization focused on non-animal testing that has served its market for more than two decades. The company describes this as part of a plan to participate more extensively in markets where the movement toward humane, non-animal safety testing has been strong.

InVitro International’s communications also reference work with external advisors to support its corporate growth plan. The company has announced an engagement with a consulting and investment banking firm to assist with business advising, management, and strategy related to its growth objectives. It has further indicated interest in enhancing its presence on the OTC Markets by applying to move from the OTC Pink market to OTCQB, citing potential benefits in visibility and credibility, particularly in connection with potential merger and acquisition targets.

Across its public statements, InVitro International consistently emphasizes several themes: the development and marketing of non-animal test technologies, alignment with global regulatory and legislative trends favoring in vitro testing, a mission tied to animal welfare, and a growth strategy that combines continued profitability with expansion through mergers and acquisitions. The company describes itself as operating in an environment shaped by prior economic challenges, including the effects of Covid-related conditions and inflation, and portrays its financial performance and strategic initiatives as responses to these conditions while maintaining its focus on non-animal safety testing.

Stock Performance

$0.0700
No recent trading
Last close: November 9, 2026
-17.2%
1 year to November 9, 2026

InVitro Intl (IVRO) closed at $0.0700 on November 9, 2026. In the 12 months to November 9, 2026, the price lost 17.2%.

See what a $1,000 investment in IVRO would be worth today

Average down calculator for IVRO

IVRO Metrics & Rankings

Market Cap
$1.6M
View ranking

Price returns through November 9, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

SEC Filings

No SEC filings available for IVRO.

Short Interest History

Last 12 Months

Short interest in InVitro Intl (IVRO) currently stands at 5.0 thousand shares, representing 0.0% of the shares outstanding. Since January 2026, short interest has decreased by 63.8%.

Days to Cover History

Last 12 Months

Days to cover for InVitro Intl (IVRO) currently stands at 13.7 days, up 157.8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since January 2026, the figure has increased by 1274%. Across the settlements charted above, it has ranged from 1.0 to 68.5 days.

IVRO Company Profile & Sector Positioning

InVitro Intl (IVRO) operates in the Diagnostics & Research industry within the broader Healthcare sector and is listed on the OTC.

Investors comparing IVRO often look at related companies in the same sector, including IDenta Corp (IDTA), Immunovia AB (IMMVF), Telo Genomics Corp (TDSGF), Hypha Labs, Inc. (FUNI), and Izotropic Corp (IZOZF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate IVRO's relative position within its industry.

Frequently Asked Questions

InVitro Intl (IVRO) has no recent trading. Its last close was $0.0700 on November 9, 2026.

The market cap of InVitro Intl (IVRO) is approximately $1.6M. Learn more about what market capitalization means .

According to its public statements, InVitro International develops and markets globally approved NON-Animal test technologies used for safety testing. The company notes that its in vitro methods are designed as alternatives to animal-based testing.

InVitro International states that it serves large industries such as cosmetics, chemical companies, and manufacturers of various adhesives. These customers use the company’s in vitro safety test methods in their operations.

The company links its business to the global movement toward sparing animals from safety testing. It describes itself as a pioneer developer and marketer of NON-Animal test technologies and emphasizes a long-standing vision of shifting industry from animal-based safety testing to in vitro testing.

The company describes a strategy that combines organic growth with mergers and acquisitions. It has discussed pursuing mergers with privately owned testing laboratories and has announced a Memorandum of Understanding to merge with a European-based non-animal testing focused organization.

InVitro International reports that its board approved a Memorandum of Understanding to merge with a European-based organization focused on non-animal testing that has served its market for more than two decades. The company views this as a way to participate more in a region where the movement toward humane non-animal safety testing began and continues to grow.

In its fiscal year communications, InVitro International highlights a long sequence of profitable years and notes that it has continued profitability despite economic challenges related to Covid and inflation. It presents this record as support for its plans to grow organically and through mergers and acquisitions.

The company notes that it has been listed on OTC Markets for multiple years and has traded on the OTC Pink market under the symbol IVRO. It has also stated an intention to apply for an uplisting to OTCQB, which it believes could increase visibility and credibility with potential merger and acquisition targets.

Yes. InVitro International has announced that it engaged Askew Kabala and Company, Inc. to act in a business advising, investment banking, management, and strategy role. This engagement is described as supporting and advancing the company’s corporate growth plan.

The company refers to increased enthusiasm for NON-Animal testing in the United States and abroad, and notes actions such as Canada’s prohibition on introducing new cosmetics if animal testing is part of their creation. It interprets these developments as supportive of its non-animal testing business and mission.